PSORIASIS (PSO)

This early-stage study tests a new drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The goal is to check safety and how the drug affects the body. Participants receive multiple doses and are monitored for side effect…

This study tests whether adding semaglutide (a drug used for diabetes and weight loss) to a standard topical cream can improve psoriasis symptoms and reduce body-wide inflammation. About 62 adults with plaque psoriasis who are overweight or have type 2 diabetes will receive eithe…

This Phase 2 trial is testing a new biologic drug called HB0017 in 200 adults with moderate to severe plaque psoriasis. Participants receive different doses and schedules of the injection to see how well it clears skin plaques and how safe it is. The study is double-blind and ran…

This early-stage study tests whether adding daily probiotics to weekly methotrexate can improve psoriasis symptoms and gut bacteria in newly diagnosed adults. 24 participants will either get probiotics plus methotrexate or methotrexate alone for 4 months. Researchers will compare…

This study tests whether a dermatologist's physical exam is better than a patient questionnaire at spotting psoriatic arthritis (PsA) in people with psoriasis. About 500 adults with psoriasis will be checked by both methods, then referred to a rheumatologist for a final diagnosis…

This early-stage study tests an experimental oral drug, LPX-TI641, in 48 adults with atopic dermatitis (eczema) or psoriasis. The main goal is to check if the drug is safe and tolerable compared to a placebo over 28 days. Researchers will also measure how the drug moves through t…

This study tests an oral medication called roflumilast in 36 adults with moderate-to-severe plaque psoriasis. Over 12 weeks, researchers will measure how much the skin improves and check for side effects. The goal is to see if this drug can help reduce symptoms like redness, scal…

This study observes how people with psoriasis receive care in different countries. Researchers will collect data from routine doctor visits to understand treatment patterns, disease severity, and quality of life. The goal is to identify gaps in healthcare delivery and improve out…

This study follows 80 adults in Canada with moderate-to-severe psoriasis who are starting the drug tildrakizumab. Researchers want to see how the treatment affects quality of life and skin clearing over one year, especially in people with darker skin tones (Fitzpatrick type III a…